Successful Completion of Second Clinical Trial on CP024 Intranasal Growth Hormone

News   Feb 13, 2013

 
Successful Completion of Second Clinical Trial on CP024 Intranasal Growth Hormone
 
 
 

RELATED ARTICLES

Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain Cancer

News

Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.

READ MORE

New Drug Class: Potential Therapeutics for Alzheimer’s Disease?

News

One step closer to an Alzheimer's treatment? Novel class of drugs more precisely blocks production of toxic forms of beta-amyloid.

READ MORE

XenoGesis and Juniper Pharma Services Strengthen Alliance

News

Campanies extend strategic alliance in early drug development services.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE